Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2949465

N.O=C(O)c1sc2c(ccc(=O)n2-c2ccccc2)c1Nc1ccc(F)cc1F

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
SMN1; SMN2 Q16637 3/20 0.37
TP53 P04637 2/20 0.37
MAPK14 Q16539 2/20 0.36
RAB9A P51151 2/20 0.36
HTT P42858 2/20 0.36
NPC1 O15118 1/20 0.36
MAPT P10636 2/20 0.36
GAA P10253 2/20 0.36
POLB P06746 2/20 0.36
RXFP1 Q9HBX9 1/20 0.36
ALOX15 P16050 1/20 0.36
CSNK2A1 P68400 1/20 0.36
G6PD P11413 1/20 0.36
MPI P34949 1/20 0.36
PHOSPHO1 Q8TCT1 1/20 0.36
HSD17B10 Q99714 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1267170 0.98 ALDH1A1 (0.44) ALDH1A1SMN1; SMN2TP53MAPK14RAB9A
SCHEMBL2949772 0.91 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2TP53MAPK14RAB9A
Lithium Ion SCHEMBL1267169 0.90 ALDH1A1 (0.42) ALDH1A1SMN1; SMN2TP53MAPK14RAB9A
SCHEMBL1266007 0.87 MAPT (0.42) ALDH1A1SMN1; SMN2TP53MAPK14HTT
SCHEMBL2955571 0.87 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2MAPK14HTTMAPT
SCHEMBL2957716 0.86 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2TP53RAB9AMAPT
SCHEMBL1266234 0.86 ALDH1A1 (0.39) ALDH1A1SMN1; SMN2TP53MAPTGAA
Ammonia Solution, Strong SCHEMBL2960210 0.85 NPC1 (0.39) ALDH1A1SMN1; SMN2TP53RAB9AHTT
SCHEMBL5667200 0.85 ALDH1A1 (0.41) ALDH1A1SMN1; SMN2TP53HTTMAPT
SCHEMBL1266269 0.85 MAP2K1 (0.40) ALDH1A1SMN1; SMN2TP53MAPK14GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK ALDH1A1 1045/4885SMN1; SMN2 3637/4885TP53 3118/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 ALDH1A1 717/4885SMN1; SMN2 3472/4885TP53 2108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.